Lunai Bioworks Implements 1-for-8 Reverse Stock Split to Avoid Nasdaq Delisting
Event summary
- Lunai Bioworks will execute a 1-for-8 reverse stock split effective May 22, 2026, reducing outstanding shares from ~36.3M to ~4.5M.
- The move aims to boost share price above Nasdaq's $1 minimum requirement after a previous 1-for-10 split in September 2025 failed to sustain compliance.
- Stockholders approved a 1-for-3 to 1-for-30 split range in a May 8 special meeting, with the board selecting the 1-for-8 ratio.
- Fractional shares will be rounded up, and adjustments will be made to outstanding options, warrants, and equity compensation plans.
The big picture
This reverse stock split reflects a common but desperate measure for biotech firms facing delisting risks. While it temporarily addresses Nasdaq's price requirements, the underlying challenge of maintaining shareholder value persists. The company's AI-driven drug discovery platform remains its core differentiator, but execution in clinical development will ultimately determine long-term viability.
What we're watching
- Compliance Sustainability
- Whether the reverse stock split will achieve lasting compliance with Nasdaq's $1 minimum bid price rule.
- Market Reaction
- How investors respond to the reduced share count and potential liquidity impacts.
- Operational Focus
- The pace at which Lunai Bioworks advances its CNS and oncology pipeline amid capital structure adjustments.
Related topics